Life Sciences Tools & Services
Price
$523.44
+1.97%Market Cap
$194.52B
Day High
$529.15
Day Low
$511.98
Thermo Fisher Scientific delivered solid Q1 FY2026 results with revenue of $11.0B (+6.2% YoY), net income of $1.65B (+9.6% YoY), and a significant jump in operating cash flow (+64.9% YoY), though long-term debt surged 26.4% reflecting major acquisition activity.
Key risk: Significant Debt Load from Acquisition Financing
Long-term debt surged 26.4% to $42.9B in Q1 FY2026, likely tied to a major acquisition. This elevated leverage increases interest expense burden and reduces financial flexibility, particularly if integration costs exceed expectations or revenue synergies are delayed.
Other Life Sciences Tools & Services companies